Authentic Holdings Inc (AHRO): Holy Moly.......almost ...every trade to...

Holy Moly.......almost ...every trade today was a heartthrob

Magnum7419 · 2025-03-24T23:23:41.5900000Z

Holy Moly.......almost ...every trade today was a heartthrob buy :) Price Size Type B/S Bid Price Ask Price Buy Ind. Total Volume Num Exch. 14:55:39 0.0018 11,196 Buy 0.0017 0.0018 576,605 25 nasd 14:55:12 0.0018 2,777 0.0017 0.0019 565,409 24 nasd 14:55:02 0.0018 10,000 Sell 0.0018 0.0019 562,632 23 nasd 14:08:28 0.0019 2,631 Buy 0.0018 0.0019 552,632 22 nasd 13:06:53 0.0019 5,000 Buy 0.0018 0.0019 550,001 21 nasd 13:06:50 0.0019 55,619 Buy 0.0018 0.0019 545,001 20 nasd 13:06:49 0.0019 14,381 Buy 0.0018 0.0019 489,382 19 nasd 13:06:49 0.0019 70,000 Buy 0.0018 0.0019 475,001 18 nasd 13:06:49 0.0019 42,106 Buy 0.0018 0.0019 405,001 17 nasd 13:06:48 0.0019 67,894 Buy 0.0018 0.0019 362,895 16 nasd 13:06:44 0.0019 110,000 Buy 0.0018 0.0019 295,001 15 nasd 12:21:25 0.0018 1 Sell 0.0018 0.0019 185,001 14 nasd 11:56:46 0.0018 89,976 Buy 0.0017 0.0018 185,000 13 nasd 11:27:24 0.0018 10,000 Buy 0.0017 0.0018 95,024 12 nasd 11:27:18 0.0018 10,000 Buy 0.0017 0.0018 85,024 11 nasd 10:56:47 0.0018 2 Buy 0.0017 0.0018 75,021 9 nasd 10:56:47 0.0018 2 Buy 0.0017 0.0018 75,019 8 nasd 10:56:47 0.0018 3 Buy 0.0017 0.0018 75,024 10 nasd 10:56:46 0.0018 10 Buy 0.0017 0.0018 75,017 7 nasd 10:56:44 0.0018 3 0.0017 0.0019 75,007 6 nasd 10:56:44 0.0018 2 0.0017 0.0019 75,004 5 nasd 10:56:44 0.0018 2 0.0017 0.0019 75,002 4 nasd 09:39:44 0.0019 9,000 Buy 0.0017 0.0019 75,000 3 nasd 09:39:30 0.0019 10,000 Buy 0.0017 0.0019 66,000 2 nasd 09:39:21 0.0019 56,000 Buy 0.0017 0.0019 56,000 1 nasd Upgrade to Real-Time Streaming Quotes Enable real-time str

Play Episode

3min

Proactive - Interviews for investors

Quantum Base to list on AIM with £5M IPO plan

Quantum Base CEO Tom Taylor joined Stephen Gunnion in the Proactive studio with more about the company’s upcoming listing on the AIM market and its breakthrough anti-counterfeiting technology. Quantum Base, founded in 2013 as a spin-out from Lancaster University, has developed an atomic fingerprint that offers 100% secure authentication of goods, scannable with any smartphone. “It tells you 100% if something is real or it's fake,” Taylor said, describing the technology as a major leap in the fight against counterfeiting. Taylor explained that the technology has applications across sectors including brand protection, pharmaceuticals, tax stamps, banknotes, passports and even aerospace parts. The firm is already working with clients globally—from North America to the Middle East—and targeting both commercial brands and government organisations. The IPO is expected to raise £5 million, with £4.70 million already committed and trading set to begin on Friday under the ticker QUBE. The retail offer remains open. “We really want to grow… AIM really helps us grow,” Taylor said, noting the listing will support product development and expansion into new verticals. Key uses of the funds will include expanding Quantum Base’s commercial team and scaling its product reach into global markets. Looking ahead, Taylor said investors should watch for announcements of new customers and entry into new industries as milestones on the path to profitability. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications to stay updated. #QuantumBase #TomTaylor #AntiCounterfeiting #AtomicFingerprint #AIMListing #IPO2025 #SmartphoneSecurity #PharmaceuticalSecurity #BrandProtection #QuantumTech #QUBE #InvestmentNews #ProactiveInvestors

Proactive - Interviews for investors

Zinnwald Lithium wins Saxony government endorsement for lithium project after robust PFS

Zinnwald Lithium PLC (LSE:ZNWD, OTC:ZNWLF) chief executive Anton du Plessis talked with Proactive's Stephen Gunnion about the company’s recently published pre-feasibility study (PFS) for its Zinnwald Lithium Project, located in Saxony, Germany. The project is designed to supply battery-grade lithium hydroxide to the European market and has now received public backing from the Saxony government. Du Plessis outlined that the PFS demonstrates a scalable, long-life mining operation, starting with 18,000 tonnes per annum of lithium hydroxide and potentially scaling to 35,000 tonnes in a second phase. He stated, “We published our PFS on Monday that showed an economic project of significant scale… a globally significant project in terms of scale.” The economics were highlighted as robust, with a post-tax NPV of €2.20 billion and an internal rate of return of approximately 20%. The location of the project — 35km south of Dresden — positions it strategically at the heart of Germany and the EU, aligning with Europe’s push for regional supply chains of critical raw materials. Du Plessis also emphasised the importance of the local endorsement, noting, “To have the public endorsement, as we had, is extremely important to us.” The next step for the company is to optimise the project in preparation for a Definitive Feasibility Study, expected in 2026. Visit Proactive's YouTube channel for more interviews like this. Don't forget to like this video, subscribe to the channel, and hit the notification bell to stay updated on future content. #Lithium #BatteryMetals #ZinnwaldLithium #GermanMining #Saxony #CriticalMinerals #EVsupplychain #LithiumHydroxide #EUrawmaterials #MiningInvestment #PFS #CleanEnergy #ZinnwaldProject

Proactive - Interviews for investors

Nexus Minerals expands Payns Find gold target

Nexus Minerals Ltd managing director Andy Tudor talked with Proactive about the latest exploration success at the Payns Find gold target, part of the company's Wallbrook Gold Project in Western Australia. Tudor described the program as “exciting” following a third air core drilling campaign that confirmed high-grade intercepts and significantly expanded the mineralised footprint. He said, “All of the attributes for a big system are here,” highlighting consistent grades of up to 5.99g/t at the extremities of a 900m by 750m target zone. The air core results revealed both supergene and fresh rock mineralisation, with around 30% of the 163 holes showing elevated geochemistry in the final metre — a strong indicator of a large underlying system. “It’s that grade in the supergene and in the fresh rock that’s got us excited,” Tudor said. He also pointed to the presence of a full suite of alteration minerals — cerussite, rutile, tourmaline, and albite — typically associated with major gold systems in the region. With the air core phase now complete, Nexus is turning to reverse circulation (RC) drill planning. Tudor confirmed that air core drilling would continue regionally, while the company prepares for a comprehensive RC program at Payns Find to test depth extensions down to 120–150m. Visit Proactive's YouTube channel for more company interviews, and don’t forget to like this video, subscribe to the channel, and hit the notification bell for future updates. #NexusMinerals #GoldExploration #ASXStocks #WallbrookProject #PaynsFind #GoldMiningWA #RCDrilling #JuniorMiners #ASXNXM #MiningNews

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Followers	249
Posts	34539
Boards Moderated	4
Alias Born	09/29/2005

Volume:	6,283,847
Day Range:	0.0022 - 0.0027
Bid:	0.0021
Ask:	0.0026
Last Trade Time:	3:59:41 PM EDT
Total Trades:	67

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AHRO Detailed Quote

Recent AHRO News

More AHRO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent AHRO News

Go Ad-Free